Connect with us

Featured

Here’s Why SNAP Stock Price Continues to Outperform The Broader Market in 2019

Joe Samuel

Published

on

Snap Inc. (SNAP Stock Report) has been a success story in 2019 after a torrid 2018 apart from a slight pop in February. SNAP stock price took a significant dip in the markets and only showed signs of recovery at the beginning of this year.

There have been bullish sentiment forming, trying to justify Snap stock price following an impressive Q2 earnings report. However, could Snap experience a pullback?

Competition from Facebook

The company’s stock price benefited greatly from its brand power. Its demographic target of young people has been one of the company’s strategies since the beginning. However, Snap faces competition from Facebook (FB Stock Report) which bought Instagram to take on Snapchat. Instagram has all the key features that Snapchat has to attract young users.

Facebook is also building a messaging app called Threads that offers constant engagement synonymous to Snapchat. With this, it is targeting the young demographic. It also has deeper pockets than Snap. This could be enough to mount a competitive onslaught and is why investors could be cautious about Snap stock.

[SPECIAL REPORT] Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key

Recession to Hurt Snap Stock Price?

Since the beginning of 2019, Snap stock price has gained more than 193%. Although shares slipped after its Q2 2019 earnings report, the company has still managed to turn a considerable profit for its shareholders. However, with the recession, the stock may not manage to maintain its lead.

Social media companies rely on ad revenue and in the middle of recession companies may be cautious on how they spend on ad revenue. Companies will most likely cut ad spending on Snapchat ahead of Facebook because of its demographic.

[SPECIAL REPORT] Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key

The volatility of Snap Stock Price

Despite impressive Q2 earnings the company did not manage to shake the criticism of the stock being wild. Since its IPO, Snap stock price has been at war with Wall Street. Its stock is a time-sensitive investment which means if you don’t quit at the opportune moment you will lose your investment.

Snap stock is a risk because the company does not give the utility other social media platform offers. So it is better to avoid the stock.

[SPECIAL REPORT] Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key

Continue Reading
Click to comment

Biotechnology

Will Biotech Stocks Soar Into 2020?

Joe Samuel

Published

on

best biotech stocks to trade now

The stock market has been on a wild ride this year and December has shown no difference. When it comes down to it, making money in the stock market is simple. But it isn’t easy; let me explain.

For instance, if a sector is on the upward trajectory then it makes complete sense to have a look at some of the stocks in that arena. But then again, even if the sector is hot, it doesn’t mean every stock within it is.

Regardless, among the sectors that have shown impressive growth over the past few years biotech remains positive. and many investors have managed to make handsome returns. Here is a look at two biotech stocks that are worth considering at this point.

Tonix Pharmaceuticals Holding

The first biotech stock that could be out into the watch list is that of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) after the company made an important announcement. Tonix announced that it has been granted a patent by the European Patent Office for “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Mannitol”.

The patent gives Tonix access to as many as 14 claims and also gives the company exclusive rights up until 2034. The development is a significant one and could have far-reaching implications for Tonix’s business in the years to come.The news was well-received by the markets as well and the stock rallied by as much as 23% on Thursday.

VBI Vaccines

The other stock that could be taken under consideration is the VBI Vaccines Inc (NASDAQ:VBIV). The company made a major announcement with regards to the Phase 1/2A study of its cancer vaccine immunotherapeutic In recurrent glioblastoma (GBM) patients medicine VB1-1901.

The company announced that it presented the data regarding the medicine at the 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology. The event in question is an influential one and is a substantial achievement for VBI. The stock rallied by as much as 50%.

Continue Reading

Featured

Stock Price Newsletter – December 13, 2019

Joe Samuel

Published

on

stock market news

StockPrice Special Report: The $40 Billion Dollar Content Gold Rush

Click For Full Report


2 Biotech Stocks To Watch Before Next Week

See For Yourself


Streaming Wars and the Future of Companies Involved

Has The Time Come?

Continue Reading

Biotechnology

2 Biotech Stocks To Watch Before Next Week

A. Lawrence

Published

on

stock_price_medicine

Biotech has been one of the hottest sectors to invest in for quite a few years. Nowadays, investors are almost always on the lookout for the next big thing from among those stocks. However, when it comes to identifying stocks, an investor needs to do his fair share of research and then decide on his next course of action.

Additionally, one could also watch the market closely and keep track of the latest movements in penny stocks in order to identify potential winners. Here is a look at two biotech stocks which could be of interest to investors.

Biotech Stocks To Watch: Marinus Pharmaceuticals

The first biotech stock to bring under consideration is Marinus Pharmaceuticals Inc (NASDAQ:MRNS)  which has made significant gains on Wednesday on the back of an important announcement.

top biotech stocks to buy

On Wednesday, the company announced that it is going to make a simultaneous public offering of its common stock and private placement. The total value of these two offerings is going to be $65 million. The news resulted in a 38% bump in the stock price in yesterday’s trading session.

Earlier this week, the company announced that it has started its Phase 2 trial for its product ganaxolone as well. The medicine in question is supposed to treat tuberous sclerosis complex and it goes without saying that it is a significant milestone for Marinus.

Biotech Stocks To Watch: Diffusion Pharmaceuticals

top biotech stocks to buy now

The other biotech stock that could be worth tracking is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN). The company announced positive data with regards to the Phase 3 study its product Trans Sodium Crocetinate (TSC) plus standard of care (SOC). The data showed that there was an improvement in the condition of patients suffering from inoperable glioblastoma multiforme.

It proved to be a major trigger for the Diffusion stock and after the announcement was made on Tuesday, the stock has rallied by as much as 31.40%. It is a stock that could be worth watching over the coming days.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com